Treating illness: Martin Dow, Biocodex ink alliance
The Alliance was made through an agreement inked recently at the Biocodex head office in Paris.
KARACHI:
Martin Dow Limited – a pharmaceutical company – has entered into an alliance with Biocodex, a multinational pharmaceutical company based in France, according to a press release. The Alliance was made through an agreement inked recently at the Biocodex head office in Paris. The agreement was signed by Martin Dow Pakistan Chairman Jawed Akhai Pakistan and Biocodex CEO Jean Marie Lefevre. Under the agreement, Martin Dow has acquired commercial rights in Pakistan to market Biocodex product, Enflor. This extension in Martin Dow’s portfolio, through the addition of renowned probiotic, the original Saccharomyces boulardii (Enflor) which is a known and tested anti-diarrheal, will provide a solution to diarrhea patients in Pakistan. Diarrhea is common in children of Pakistan because of their exposure to contaminated food and water. The severity of diarrhea can vary from mild to life threatening. It is therefore important that the illness is properly managed and treated, said the release.
Published in The Express Tribune, March 12th, 2015.
Like Business on Facebook, follow @TribuneBiz on Twitter to stay informed and join in the conversation.
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ